Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Natalie J. Kurganovs,
Patrick J. McCoy,
Colleen C. Nelson,
Vanessa M. Hayes,
Niall M. Corcoran,
Christopher M. Hovens.
Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the
DNA or epigenetic machinery of a patient. An emerging field in cancer treatment targets key
aberrations arising from the mutational landscape of an individual patient’s disease rather than
employing a cancer-wide cytotoxic therapy approach. In prostate cancer in particular, where there is an observed variation
in response to standard treatments between patients with disease of a similar pathological stage and grade, mutationdirected
treatment may grow to be a viable tool for clinicians to tailor more effective treatments. This review will describe
a number of mutations across multiple forms of cancer that have been successfully antagonised by targeted therapeutics
including their identification, the development of targeted compounds to combat them and the development of resistance
to these therapies. This review will continue to examine these same mutations in the treatment and management of
prostate cancer; the prevalence of targetable mutations in prostate cancer, recent clinical trials of targeted-agents and the
potential or limitations for their use.
Keywords: Precision medicine, prostate cancer, targeted therapeutics.
Rights & PermissionsPrintExport